Fmr LLC Has $513.04 Million Position in Bristol-Myers Squibb Co (BMY)

Share on StockTwits

Fmr LLC trimmed its position in Bristol-Myers Squibb Co (NYSE:BMY) by 0.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,870,043 shares of the biopharmaceutical company’s stock after selling 24,274 shares during the quarter. Fmr LLC owned about 0.60% of Bristol-Myers Squibb worth $513,044,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in Bristol-Myers Squibb by 1.0% during the 3rd quarter. Vanguard Group Inc. now owns 128,376,159 shares of the biopharmaceutical company’s stock valued at $7,969,593,000 after buying an additional 1,229,553 shares in the last quarter. Vanguard Group Inc grew its holdings in Bristol-Myers Squibb by 1.0% during the 3rd quarter. Vanguard Group Inc now owns 128,376,159 shares of the biopharmaceutical company’s stock valued at $7,969,593,000 after buying an additional 1,229,553 shares in the last quarter. BlackRock Inc. grew its holdings in Bristol-Myers Squibb by 0.9% during the 4th quarter. BlackRock Inc. now owns 115,573,078 shares of the biopharmaceutical company’s stock valued at $6,007,489,000 after buying an additional 999,193 shares in the last quarter. Dodge & Cox grew its holdings in Bristol-Myers Squibb by 0.8% during the 3rd quarter. Dodge & Cox now owns 32,969,186 shares of the biopharmaceutical company’s stock valued at $2,046,727,000 after buying an additional 264,100 shares in the last quarter. Finally, Northern Trust Corp grew its holdings in Bristol-Myers Squibb by 4.4% during the 4th quarter. Northern Trust Corp now owns 22,576,884 shares of the biopharmaceutical company’s stock valued at $1,173,547,000 after buying an additional 954,877 shares in the last quarter. 74.28% of the stock is owned by institutional investors.

NYSE BMY opened at $46.02 on Wednesday. The company has a quick ratio of 1.50, a current ratio of 1.61 and a debt-to-equity ratio of 0.40. The company has a market cap of $75.98 billion, a PE ratio of 11.68, a PEG ratio of 2.39 and a beta of 0.79. Bristol-Myers Squibb Co has a one year low of $44.30 and a one year high of $63.69.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, January 24th. The biopharmaceutical company reported $0.94 EPS for the quarter, beating analysts’ consensus estimates of $0.85 by $0.09. The firm had revenue of $5.97 billion during the quarter, compared to the consensus estimate of $5.95 billion. Bristol-Myers Squibb had a return on equity of 48.99% and a net margin of 21.95%. The company’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.68 EPS. On average, sell-side analysts expect that Bristol-Myers Squibb Co will post 4.16 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be given a dividend of $0.41 per share. The ex-dividend date of this dividend is Thursday, April 4th. This represents a $1.64 dividend on an annualized basis and a dividend yield of 3.56%. Bristol-Myers Squibb’s dividend payout ratio is currently 41.21%.

A number of brokerages have issued reports on BMY. Zacks Investment Research raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $60.00 price objective for the company in a report on Tuesday, March 5th. BMO Capital Markets reaffirmed a “buy” rating and set a $60.00 price objective on shares of Bristol-Myers Squibb in a report on Thursday, January 3rd. Credit Suisse Group reaffirmed a “hold” rating and set a $59.00 price objective on shares of Bristol-Myers Squibb in a report on Friday, February 15th. Bank of America cut their price objective on shares of Bristol-Myers Squibb from $53.00 to $51.00 and set a “neutral” rating for the company in a report on Tuesday, February 19th. Finally, Morgan Stanley set a $54.00 price objective on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a report on Thursday, December 20th. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating and six have given a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $59.13.

WARNING: “Fmr LLC Has $513.04 Million Position in Bristol-Myers Squibb Co (BMY)” was originally posted by Macon Daily and is the property of of Macon Daily. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright law. The original version of this piece of content can be read at https://macondaily.com/2019/04/17/fmr-llc-has-513-04-million-position-in-bristol-myers-squibb-co-bmy.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Featured Article: Diversification For Individual Investors

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.